Literature DB >> 32648118

Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.

Melissa Pilco Teran1, Ana Merino Ribas2, Nadia Martin Alemany2, Xoana Barros Freiria2, Jordi Rubio Casadevall3, Ferran Pérez Bueno4, Isabel García Méndez2, Marcela Castillo Devia2, Cristina Noboa Paez2, Pere Torguet Escuder2, Jordi Calabia Martínez2.   

Abstract

Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.

Entities:  

Keywords:  Allergic acute tubulointerstitial nephritis; Medullary thyroid carcinoma; Tyrosine kinase inhibitor; Vandetanib

Mesh：

Substances：

Year:  2020        PMID： 32648118     DOI： 10.1007/s10637-020-00973-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  10 in total

Review 1.  Drug-induced acute interstitial nephritis.

Authors:  Mark A Perazella; Glen S Markowitz
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

Review 2.  Management of treatment-related toxicities in advanced medullary thyroid cancer.

Authors:  Marcia S Brose; Keith C Bible; Laura Q M Chow; Jill Gilbert; Carolyn Grande; Francis Worden; Robert Haddad
Journal:  Cancer Treat Rev       Date:  2018-04-22       Impact factor: 12.111

Review 3.  Cabozantinib in Thyroid Cancer.

Authors:  Poupak Fallahi; Silvia M Ferrari; Flavia Di Bari; Gabriele Materazzi; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Recent Pat Anticancer Drug Discov       Date:  2015       Impact factor: 4.169

4.  Treatment of Drug-Induced Acute Tubulointerstitial Nephritis: The Search for Better Evidence.

Authors:  Dennis G Moledina; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-05       Impact factor: 8.237

5.  Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity.

Authors:  Medha Airy; Rajeev Raghavan; Luan D Truong; Garabed Eknoyan
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

6.  Biopsy-proven acute interstitial nephritis, 1993-2011: a case series.

Authors:  Angela K Muriithi; Nelson Leung; Anthony M Valeri; Lynn D Cornell; Sanjeev Sethi; Mary E Fidler; Samih H Nasr
Journal:  Am J Kidney Dis       Date:  2014-06-11       Impact factor: 8.860

7.  Acute tubulointerstitial nephritis in Scotland.

Authors:  A Valluri; L Hetherington; E Mcquarrie; S Fleming; D Kipgen; C C Geddes; B Mackinnon; S Bell
Journal:  QJM       Date:  2014-11-28

Review 8.  Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.

Authors:  Maria E Cabanillas; Mabel Ryder; Camilo Jimenez
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

9.  Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis.

Authors:  E González; E Gutiérrez; C Galeano; C Chevia; P de Sequera; C Bernis; E G Parra; R Delgado; M Sanz; M Ortiz; M Goicoechea; C Quereda; T Olea; H Bouarich; Y Hernández; B Segovia; M Praga
Journal:  Kidney Int       Date:  2008-01-09       Impact factor: 10.612

10.  Effect of steroids and relevant cytokine analysis in acute tubulointerstitial nephritis.

Authors:  Donghwan Yun; Myoung-Jin Jang; Jung Nam An; Jung Pyo Lee; Dong Ki Kim; Ho Jun Chin; Yon Su Kim; Dong-Sup Lee; Seung Seok Han
Journal:  BMC Nephrol       Date:  2019-03-12       Impact factor: 2.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.